Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

NCT03414450 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped Withdrawal requested by D3

Conditions

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)
Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

Interventions

DRUG: ETC-1907206
DRUG: dasatinib

Sponsor

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Collaborators

[object Object]